Lung Cancer Clinical Trial
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
Summary
Phase 2 study of subjects with ALK positive, advanced NSCLC who have failed up to 3 prior therapies. The study will take place globally at multiple study centers. Subjects will be enrolled to receive ganetespib one time per week for three weeks followed by a rest week; and will repeat this schedule until the cancer gets worse or the subject is unable to tolerate ganetespib. The primary goal of the study is to determine how ganetespib is tolerated and how active it is in ALK positive NSCLC.
Eligibility Criteria
Inclusion Criteria:
Males or females aged 18 years or older
Pathological confirmation of advanced NSCLC
Evidence of a translocation or an inversion event involving the ALK gene locus
ECOG Performance Status 0 or 1
Exclusion Criteria:
Prior therapy with ALK-targeted agents
Prior treatment with Hsp90 inhibitor
Known EGFR activating mutation
Presence of active or untreated central nervous system (CNS) metastases
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Tampa Florida, 33612, United States
Cleveland Ohio, 44195, United States
Hamilton Ontario, ON L8, Canada
Ottawa Ontario, K1H 8, Canada
Toronto Ontario, M5G 2, Canada
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.